×
About 384,590 results
FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
http://hugin.info/152918/R/2233733/878824.pdf

Feb 6th, 2019 - The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Cablivi is the first FDA approved therapy specifically indicated for the treatment of aTTP.

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study.
https://meetinglibrary.asco.org/record/170343/abstract

Feb 16th, 2019 - A phase 1b study of pembro (anti–PD-1) plus axi (VEGFR-TKI) showed promising antitumor activity and manageable safety in patients (pts) with previously untreated mRCC. The global, open-label, phase 3 KEYNOTE-426 study assessed the efficacy and safety of pembro + axi vs sunitinib as first-line therapy for mRCC (NCT02853331).

Relapse prevention interventions for smoking cessation
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003999.pub5/full

Feb 15th, 2019 - Behavioural interventions that teach people to recognise situations that are high risk for relapse along with strategies to cope with them provided no worthwhile benefit in preventing relapse in assisted abstainers, although unexplained statistical heterogeneity means we are only moderately certain of this. In people who have successfully quit smoking using pharmacotherapy, there were mixed res...

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
https://www.nejm.org/doi/full/10.1056/NEJMoa1814017

Feb 14th, 2019 - Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy have a worse prognosis than those who have no residual cancer. Trastuzumab emtansine (T-DM1), an antibody–drug conjugate of trastuzumab and the cytotoxic agent emtansine (DM1), a maytansine derivative and microtubule inhibitor, provides...

Janssen Announces Preliminary Results from Phase 2 GALAHAD Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects (DRD)
https://www.janssen.com/janssen-announces-preliminary-results-phase-2-galahad-study-adults-metastatic-castration-resistant

Feb 14th, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson will present today at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) early results from the ongoing Phase 2 GALAHAD study evaluating niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA-repair pathway defects (DRD)...

Further Progress for Patients with Breast Cancer
https://www.nejm.org/doi/full/10.1056/NEJMe1816059

Feb 14th, 2019 - Substantial progress has been made over the past 50 years in the evaluation and treatment of patients with breast cancer, leading to a nearly 40% decrease in mortality from this disease and associated reductions in complications of treatment. This progress has occurred with the understanding that breast cancer is not one but several diseases with biologically driven subtypes.2 Each of these sub...

Genitourinary Cancers Symposium Poster Session A: Prostate Cancer
https://gucasym.org/program/poster-sessions/poster-session-a

Feb 14th, 2019 - Abstract 202: Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.

Combination therapy improves survival in advanced kidney cancer
https://www.bci.qmul.ac.uk/en/news/general-news/item/combination-therapy-improves-survival-in-advanced-kidney-cancer

Feb 13th, 2019 - A combination therapy has shown powerful anticancer responses in patients with a type of advanced kidney cancer in a new international phase III clinical trial (KEYNOTE-426). Treatment with the combination therapy resulted in significant increases in overall survival when compared with the current standard of care, and the findings will help to provide a vital new treatment option for patients ...

FDA approves daratumumab split-dosing regimen in multiple myeloma
https://www.healio.com/hematology-oncology/myeloma/news/online/%7B1716890b-f603-4c3f-9e03-dc86ffad3a27%7D/fda-approves-daratumumab-split-dosing-regimen-in-multiple-myeloma

Feb 13th, 2019 - The FDA approved a split-dosing regimen for daratumumab that will allow the first infusion to be administered over two consecutive days for patients with multiple myeloma, according to a press release from the drug’s manufacturer. The approval was based on data from the phase 1b EQUULEUS trial that showed comparable pharmacokinetic concentrations of daratumumab (Darzalex, Janssen Pharmaceutical...

Tobacco Use By Youth Is Rising
https://www.cdc.gov/vitalsigns/youth-tobacco-use/

Feb 12th, 2019 - Tobacco product use among US youth is increasing. More than 1 in 4 high school students and about 1 in 14 middle school students in 2018 had used a tobacco product in the past 30 days. This was a considerable increase from 2017, which was driven by an increase in e-cigarette use. E-cigarette use increased from 11.7% to 20.8% among high school students and from 3.3% to 4.9% among middle school s...

2019 GU Cancers Symposium: KEYNOTE-426: Pembrolizumab Plus Axitinib vs Sunitinib in Advanced Renal Cell Carcinoma
http://ascopost.com/News/59740

Feb 12th, 2019 - Results from the randomized, phase III KEYNOTE-426 clinical trial show that first-line therapy with a combination of pembrolizumab and axitinib extended both overall survival (OS) and progression-free survival (PFS) for patients with clear cell metastatic renal cell carcinoma compared with the current standard of care, sunitinib. Findings from this international study will be presented by Powle...

U.S. FDA Approves DARZALEX® (daratumumab) Split-Dosing Regimen
https://www.janssen.com/us-fda-approves-darzalex-daratumumab-split-dosing-regimen

Feb 12th, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved a split-dosing regimen for DARZALEX® (daratumumab), providing healthcare professionals and patients with multiple myeloma an option to split the first infusion over two consecutive days. The U.S. FDA approval is based on data from the Phase 1b EQUULEUS (MMY1001...

Investigational multitargeted kinase inhibitors in development for head and neck neoplasms
https://www.tandfonline.com/doi/abs/10.1080/13543784.2019.1581172?journalCode=ieid20

Feb 12th, 2019 - Despite advances in treatment, head and neck squamous cell carcinoma (HNSCC) survival rates remain stagnant. Current treatment is associated with significant toxicities and includes chemotherapy, radiation, surgery and few targeted treatments. Targeted treatments, epidermal growth factor receptor (EGFR)-targeted agent, cetuximab, and immune checkpoint inhibitors, pembrolizumab and nivolumab, sh...

Mammography, improved treatment prevented up to 614,500 breast cancer deaths since 1989 SHOW CITATION
https://www.healio.com/hematology-oncology/breast-cancer/news/in-the-journals/%7Bec9ae85f-6915-4f93-ad06-c914a1347afc%7D/mammography-improved-treatment-prevented-up-to-614500-breast-cancer-deaths-since-1989

Feb 11th, 2019 - Mammography screening and improved treatments have prevented between 384,000 and 614,500 breast cancer deaths since 1989, according to a study published in Cancer. “Recent reviews of mammography screening have focused media attention on some of the risks of mammography screening, such as callbacks for additional imaging and breast biopsies, downplaying the most important aspect of screening — t...

FDA grants priority review to Keytruda for first-line treatment of advanced head and neck cancer
https://www.healio.com/hematology-oncology/head-neck-cancer/news/online/%7Bf7be7f0c-f55a-4770-89bf-caf27f834e43%7D/fda-grants-priority-review-to-keytruda-for-first-line-treatment-of-advanced-head-and-neck-cancer

Feb 11th, 2019 - The FDA granted priority review to pembrolizumab for first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma. The designation applies to use of pembrolizumab (Keytruda, Merck) — an anti-PD-1 agent — as monotherapy or in combination with platinum and 5-FU chemotherapy.

Genitourinary Cancers Symposium - Poster Sessions
https://gucasym.org/program/poster-sessions

Feb 11th, 2019 - View Poster Sessions from the Symposium.

Breast cancer deaths averted over 3 decades
https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.31954

Feb 11th, 2019 - Background From 1975 to 1990, female breast cancer mortality rates in the United States increased by 0.4% per year. Since 1990, breast cancer mortality rates have fallen between 1.8% and 3.4% per year, a decrease that is attributed to increased mammography screening and improved treatment. Methods The authors used age‐adjusted female breast cancer mortality rate and population data from the Sur...

Phase II Trial Shows Novel, Radiolabeled PSMA-Targeted Treatment Provides High Response Rates in Men With Metastatic Prostate Cancer
https://www.asco.org/about-asco/press-center/news-releases/phase-ii-trial-shows-novel-radiolabeled-psma-targeted

Feb 11th, 2019 - A single-arm, phase II trial in men with PSMA-positive metastatic, castration-resistant prostate cancer (mCRPC) that progressed despite standard therapies, found that in the majority of men, the cancers were responsive to treatment with a novel, targeted radiation therapy called Lutetium-177 PSMA-617 (LuPSMA). This is the first prospective study of LuPSMA, part of a potential new class of treat...

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
http://ascopubs.org/doi/full/10.1200/JCO.18.00915

Feb 11th, 2019 - Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple lines of treatment after becoming refractory to standard therapies. Duvelisib was approved by the Food and Drug Administration for relapsed or refractory (RR) chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL) and RR follicular lymphoma (FL) after two or more prior systemic therapies. On the...

Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015
https://jamanetwork.com/journals/jama/fullarticle/2724897?resultClick=1

Feb 11th, 2019 - Historically, most patients with low-risk prostate cancer (clinical category T1c-T2a, prostate-specific antigen level <10 ng/mL, and Gleason 6 disease) were treated with radical prostatectomy, while radiotherapy-based treatment was the favored approach for high-risk localized prostate cancer. However, conservative management of low-risk prostate cancer with active surveillance or watchful waiti...